MedTrace Logo

Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19

NCT04733651 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2021-02-05

No results posted yet for this study

Summary

The purpose of this study is to investigate the clinical efficacy of Isoquercetin in preventing disease progression and symptoms improvement in mild-to-moderate hospitalised COVID-19 patients.

Conditions

  • Covid19

Interventions

DRUG

Hospital standard of care for COVID-19

Standard care for COVID-19 as per the hospital guidelines

DRUG

Isoquercetin

Daily 1000 mg Isoquercetin as 4 capsules

Sponsors & Collaborators

  • Nepal Health Research Council

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-20
Primary Completion
2021-05-20
Completion
2021-08-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733651 on ClinicalTrials.gov